Across TCGA pan-cancer cohorts, ARL16 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of ARL16’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ARL16 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARL16 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

LSCC are the cancer types where ARL16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	All	−0.531	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ARL16 RNA expression & survival · all ARL16 data types